Jeffrey Skene

To provide funding for the Canadian Collaboration to Cure ALS, to establish a coordinated national research ecosystem through which every Canadian living with ALS can participate in, and benefit from, cutting-edge science that will accelerate discoveries by Canadian researchers, advance understanding of the disease, and enable the development of therapies to treat this devastating terminal illness with greater precision. Sources of funding are to be determined. Policies or programs related to access to care and potential treatments for the ALS Community. Amendment to the compassionate care program to make it more accessible to caregivers and to increase the length of the benefit.

The creation of a policy that would address making psychedelic medicines available to treat mental illnesses.

Increased federal investment in health-related research. Advocating for implementation of Canada's drugs for rare diseases strategy. With respect to disability, we advocate for recognition of and supports for people with episodic disabilities. In terms of science and technology, we work toward the development of precision and personalized medicines that target the basic defect of cystic fibrosis. We are exploring how the federal government may support these efforts through partnership and funding. In terms of research and development, we lobby for support of cystic fibrosis research initiatives that improve the health and wellness of Canadians living with cystic fibrosis. Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases. Advocating to stop the regulatory changes to the Patented Medicines Price Review Board (PMPRB).